Targeting the RBP4-STRA6 signaling pathway offers therapeutic potential in mitigating insulin resistance and β-cell dysfunction (Huang et al., 2021; Perumalsamy et al., 2021). The gene discussed is RBP4; the disease is Insulin resistance.